Study on Breast Cancer Prognosis Using Multiplex Assay
Author Information
Author(s): Ferrero J M, Etienne M C, Formento J L, Francoual M, Rostagno P, Peyrottes I, Ettore F, Teissier E, Leblanc-Talent P, Namer M, Milano G
Primary Institution: Oncopharmacology Unit, Centre Antoine Lacassagne
Hypothesis
The study investigates the long-term prognostic value of MDR1, MRP, and p53 in node-positive breast cancer patients receiving anthracycline-based adjuvant therapy.
Conclusion
The study found that while p53 protein levels were significantly higher in ER-negative tumors, neither MDR1 nor MRP expression had a significant influence on progression-free or specific survival.
Supporting Evidence
- MDR1 expression varied within an 11-fold range.
- P53 protein was significantly higher in ER-negative than in ER-positive tumors.
- The higher the p53, the lower the MDR1 expression.
- Significantly greater MDR1 expression was observed in grade I tumors.
- MRP was correlated with the S phase: the greater the MRP, the lower the S phase.
Takeaway
This study looked at how certain proteins in breast cancer tumors might help predict how well patients will do after treatment, but they didn't find strong links to survival.
Methodology
Patients underwent tumor resection, irradiation, and adjuvant chemotherapy, with protein expressions analyzed using specific assays.
Limitations
The study did not find significant relationships between MDR1, MRP, and survival outcomes.
Participant Demographics
Mean age was 53.7 years, with a range of 28 to 79 years, and 54 patients were post-menopausal.
Statistical Information
P-Value
P = 0.039 for p53 in ER-negative vs. ER-positive tumors; P = 0.015 for p53 and MDR1 relationship.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website